Article Details

NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours

Retrieved on: 2025-03-11 17:59:04

Tags for this article:

Click the tags to see associated articles and topics

NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours. View article details on hiswai:

Excerpt

The gold standard of business intelligence. Find out more. It aims to determine the recommended dose(s) for the therapy's expansion when used as a ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo